Kitabis Pak Wins American Package Design Award

RICHMOND, Va., June 3, 2015 /PRNewswire/ -- PARI Respiratory Equipment has won a 2015 American Package Design Award for Kitabis Pak^®.  Kitabis Pak, approved by the FDA on December 2, is the first co-packaging of generic tobramycin inhalation solution with a PARI LC PLUS^® Nebulizer for patients with cystic fibrosis.

"This award highlights all the hard work we put into this unique product offering of nebulized drug and device.  In creating a package that is easy for patients to use, we also wanted to convey that the components suit each other. By using complimentary colors, the packaging visually reflects the fact that tobramycin inhalation solution was designed to be delivered by the PARI LC PLUS Nebulizer," said Jan Zimmermann, portfolio manager for Kitabis Pak. 

"Not only is the packaging attractive, it ensures that with every prescription, every patient has access to the only FDA approved nebulizer handset for tobramycin inhalation solution and the same nebulizer used in clinical trials. It is gratifying that the creative package for this important combination of therapy and delivery device puts us alongside other design winners, such as Target, Burt's Bees, Revlon, and Tory Burch," said Ashley Weigand, director of marketing for PARI Respiratory Equipment.

PARI Respiratory Equipment exclusively markets Kitabis Pak and the compressor access program called PARI PROVIDE.  Kitabis Pak is a new standard for nebulized drugs similar to asthma & COPD inhalers where the drug and device are prescribed and dispensed together.  The price of Kitabis Pak is comparable to the price of generic tobramycin drug alone.  PARI PROVIDE takes the program one step further by providing patients with the only FDA approved compressor to deliver tobramycin inhalation solution.

About Kitabis Pak

Kitabis Pak (co-packaging of tobramycin inhalation solution and PARI LC PLUS Reusable Nebulizer) is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with P. aeruginosa.  Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.

Full product and prescribing information on Kitabis Pak and PARI PROVIDE is online at: www.Kitabis.com.

About Cystic Fibrosis

Cystic fibrosis, a life-threatening disease affecting 30,000 American patients, involves a genetic mutation that results in poorly hydrated, thickened mucus secretions in the lungs.

About American Package Design Awards

The American Package Design Awards recognize excellence in packaging.  In 2015, the contest generated 2,025 entries.  Graphic Design USA runs the contest and has produced a graphic design magazine for 52 years.

About PARI Respiratory Equipment, Inc.

PARI is a leading, worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, cystic fibrosis, RSV, VAP, and HAP.  PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them. PARI is considered the gold standard for aerosol delivery for nebulizer therapies.  Featured products include the PARI LC PLUS Reusable Nebulizer, Vortex Holding Chamber, and the drug-specific eFlow Technology platform.

SOURCE PARI Respiratory Equipment